Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratification insights that directly impact current and future treatment decisions. Integrating germline testing early in your patients’ diagnostic workup is now easier than ever.

Patients with localized prostate cancer and a BRCA mutation are:

  • 6x more likely to die from prostate cancer within 5 years
  • 4x more likely to develop metastasis within 5 years
  • Live ~7 years less on average

If you would like to learn more about BRACAnalysis CDx® or myRisk®, click here.

Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.